PuraMatrix® has demonstrated efficacy in multiple models for hemostasis (CE Mark approved, trade name PuraStat®), tissue regeneration, acute myocardial infarction, therapeutic protein and stem cell delivery, and CNS injury. PuraMatrix® can re-hydrate and provide mechanical support for disc height collapse in degenerated IVDs, anti-adhesion, polyp resection, and bone formation. PuraMatrix® has also been used to repair and restore visual function in the CNS after damage.
PuraMatrix® can be combined with many different cell types, biologically-active agents (i.e., platelet rich plasma), proteins (growth factors, cytokines, or antibodies) and siRNA or drugs prior to administration. Specific growth factors alone or in combination with other biologically active agents such as cytokines (epidermal growth factor, nerve growth factor, transforming growth factor-alpha and beta, platelet-derived growth factor, insulin-like growth factor, vascular endothelial growth factor, et al) have been demonstrated to be effective in animal models in combination with PuraMatrix®.
Click here for peer-reviewed publications of PuraMatrix® in Drug Delivery clinical applications.